{
    "nct_id": "NCT06714253",
    "official_title": "A Phase I/IIa, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Intraductal Administration of RXRG001 to Parotid Gland(s) in Adults with Radiation-Induced Xerostomia and Hyposalivation",
    "inclusion_criteria": "Inclusion Criteria*\n\n1. At least 18 years of age\n2. History of radiation treatment or chemoradiotherapy for head and neck cancer for stage 2 or higher\n3. Free from recurrence of your cancer and never have had another form of cancer for at least 2 years\n4. Suffering from xerostomia and/or hyposalivation and have xerostomia symptoms which were not resolved after treatment for at least 3 months\n5. Both parotid glands on imaging examination\n\nExclusion Criteria*\n\n1. Any active infection\n2. Heart failure, reduced kidney function or uncontrolled diabetes (Hemoglobin A1c >8%)\n3. History of autoimmune diseases known to potentially affect the salivary glands\n4. Any malignancy, other than head and neck cancer within the past 3 years except for certain skin and cervical cancers\n5. Active smoker or use tobacco products or have a history of substance or alcohol abuse\n\n   * Other criteria apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}